As of June 30, 2026, TRANSGENE S.A. carries a market capitalization of 230.63M, placing it among publicly traded companies globally. Its enterprise value stands at 124.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 230.63M |
| Enterprise Value | 124.56M |
TRANSGENE S.A.'s next confirmed earnings release is scheduled for March 31, 2027.
| Earnings Date | 3/31/2027 |
As of June 30, 2026, TRANSGENE S.A. has 278.26M shares outstanding.
| Shares Outstanding | 278.26M |
These figures are as of June 30, 2026.
| PB Ratio | 1.85 |
| P/TBV Ratio | 1.85 |
As of June 30, 2026, TRANSGENE S.A. maintains a current ratio of 9.40, meaning it holds 9.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.40 |
| Quick Ratio | 8.68 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 156.00 |
As of the close on October 26, 2026, TRANSGENE S.A.'s stock has gained approximately 6.46% over the past 52 weeks.
| 52-Week Price Change | 6.46% |
| 50-Day Moving Average | 2.07 |
These figures are as of June 30, 2026. Total book value stands at 124.75M, with working capital of 102.68M providing operational flexibility.
| Cash & Cash Equivalents | 106.07M |
| Net Debt | -4.85M |
| Equity (Book Value) | 124.75M |
| Book Value Per Share | 0.45 |
| Working Capital | 102.68M |
TRANSGENE S.A.'s most recent stock split took place on June 18, 2019 with a 39:40 split ratio.
| Last Split Date | 6/18/2019 |
| Split Ratio | 39:40 |
Already premium?